Shots: TULIP 1 P-III trial with didn’t meet SRI4@12mos in moderate-to-severe SLE patients TULIP study includes two P-III trials TULIP 1 (N=460) in ratio (1:2:2) for 52 wks. administering of 150,300mg anifrolumab IV or PBO q4w; TULIP 2(N=373) in ratio (1:1) 300mg anifrolumab IV or PBO q4w, evaluating safety and efficacy Anifrolumab is also being […]Read More
Tags : TULIP 1 P-III
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US